Cutera (NASDAQ:CUTR) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Cutera (NASDAQ:CUTR) in a report released on Friday. The firm issued a sell rating on the medical device company’s stock.

Cutera Price Performance

Shares of NASDAQ CUTR opened at $0.36 on Friday. The stock has a market capitalization of $7.34 million, a PE ratio of -0.06 and a beta of 1.26. Cutera has a one year low of $0.28 and a one year high of $4.97. The business’s fifty day moving average price is $0.47 and its 200-day moving average price is $0.90.

Hedge Funds Weigh In On Cutera

A number of hedge funds and other institutional investors have recently modified their holdings of CUTR. Squarepoint Ops LLC grew its holdings in Cutera by 164.5% in the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock worth $172,000 after acquiring an additional 70,870 shares during the last quarter. Bank of Montreal Can raised its holdings in Cutera by 14.2% in the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock worth $455,000 after purchasing an additional 35,248 shares in the last quarter. Finally, Ground Swell Capital LLC purchased a new stake in shares of Cutera in the 2nd quarter worth about $37,000. 90.70% of the stock is currently owned by hedge funds and other institutional investors.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.